These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34841193)

  • 1. Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India.
    Basavaraja CK; Sebastian J; Ravi MD; John SB
    Ther Adv Vaccines Immunother; 2021; 9():25151355211055833. PubMed ID: 34841193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active surveillance of adverse events following COVID-19 vaccines in a tertiary care hospital.
    Cherian NM; Durai DA; Jaisel M; Sharma D; Sebastian J; Basavaraja CK; Mathew M
    Ther Adv Vaccines Immunother; 2023; 11():25151355231193975. PubMed ID: 37641637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India.
    Gandhi AP; Venkatesh U; Murali N
    Indian Heart J; 2023; 75(2):139-144. PubMed ID: 36863611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active surveillance of adverse events following immunization (AEFI): a prospective 3-year vaccine safety study.
    Sebastian J; Gurumurthy P; Ravi MD; Ramesh M
    Ther Adv Vaccines Immunother; 2019; 7():2515135519889000. PubMed ID: 31799496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India.
    Chakraborty A; Reval N; Kamath L
    Cureus; 2022 Feb; 14(2):e21809. PubMed ID: 35291520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic causality assessment of adverse events following HPV vaccines: Analysis of current data from Apulia region (Italy).
    Tafuri S; Fortunato F; Gallone MS; Stefanizzi P; Calabrese G; Boccalini S; Martinelli D; Prato R
    Vaccine; 2018 Feb; 36(8):1072-1077. PubMed ID: 29358055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center.
    Prasad N; Bansal SB; Yadav B; Manhas N; Yadav D; Gautam S; Kushwaha R; Singh A; Bhadauria D; Yachha M; Behera MR; Kaul A
    Front Immunol; 2022; 13():911738. PubMed ID: 35844596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018-2020.
    Stefanizzi P; Bianchi FP; Martinelli A; Di Lorenzo A; De Petro P; Graziano G; Lattanzio S; Diella G; Stella P; Ancona D; Tafuri S
    Hum Vaccin Immunother; 2022 Dec; 18(1):2041359. PubMed ID: 35201942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Yakum MN; Mengouo MN; Genton B
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1170-1178. PubMed ID: 27174237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causality assessment of serious and severe adverse events following immunization in India: a 4-year practical experience.
    Singh AK; Wagner AL; Joshi J; Carlson BF; Aneja S; Boulton ML
    Expert Rev Vaccines; 2018 Jun; 17(6):555-562. PubMed ID: 29865876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    van der Boor SC; Schmitz-de Vries ETJ; Smits D; Scholl JHG; Rolfes L; van Hunsel F
    Vaccine; 2023 Jun; 41(29):4319-4326. PubMed ID: 37286408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of the revised WHO causality assessment protocol for adverse events following immunization in India.
    Singh AK; Wagner AL; Joshi J; Carlson BF; Aneja S; Boulton ML
    Vaccine; 2017 Jul; 35(33):4197-4202. PubMed ID: 28648545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, India.
    Kamble B; Bashar MA; Mishra CP
    Cureus; 2022 Feb; 14(2):e21848. PubMed ID: 35273834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and clinical characteristics of adverse neurological events and stroke-like syndrome associated with immune stress-related response after COVID-19 vaccination in 2021 from Thailand.
    Sirisuk W; Limvorapitak W; Lolekha P; Methaset K; Kulkantrakorn K
    Clin Neurol Neurosurg; 2023 Aug; 231():107804. PubMed ID: 37295197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events following immunization in children: retrospective analysis of spontaneous reports over a decade.
    Aagaard L; Hansen EW; Hansen EH
    Eur J Clin Pharmacol; 2011 Mar; 67(3):283-8. PubMed ID: 21079934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Events Following Immunization Among Children Under Two Years of Age: A Prospective Observational Study From North India.
    Mittal S; Rawat C; Gupta A; Solanki HK; Singh RK
    Cureus; 2023 Apr; 15(4):e38356. PubMed ID: 37266060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19.
    Stefanizzi P; Bianchi FP; Spinelli G; Amoruso F; Ancona D; Stella P; Tafuri S
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-6. PubMed ID: 34435938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Profile of Recommended Vaccinations in Adolescents: Data from Surveillance of Adverse Events Following Immunization in Puglia (Italy), 2016-2020.
    Di Lorenzo A; Bianchi FP; Martinelli A; Lattanzio S; Carbonara A; Diella G; Tafuri S; Stefanizzi P
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.